Lung cancer in never smokers: Disease characteristics and risk factors

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 3, 2013, Pages 494-503

  Pallis, Athanasios G ^a   Syrigos, Konstantinos N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

EGFR; Lung cancer; Never smokers; NSCLC; Smoking

Indexed keywords

CARCINOGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROTEIN TYROSINE KINASE; RADON;

ALK GENE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DNA REPAIR; ENVIRONMENTAL EXPOSURE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HER-2 GENE; HEREDITY; HIGH RISK POPULATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MYCOBACTERIUM TUBERCULOSIS; OCCUPATIONAL EXPOSURE; PASSIVE SMOKING; REVIEW; RISK FACTOR; ROS1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL CELL CARCINOMA; SMOKING; SQUAMOUS CELL CARCINOMA; WART VIRUS;

EGFR; LUNG CANCER; NEVER SMOKERS; NSCLC; SMOKING;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RISK FACTORS; SMOKING;

EID: 84888290537     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.06.011     Document Type: Review

References (104)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61:69-90.
2. Doll R., Hill A.B. Smoking and carcinoma of the lung; preliminary report. British Medical Journal 1950, 2:739-748.
3. Doll R., Peto R., Boreham J., Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004, 328:1519.
4. The Health Consequences of Smoking: A Report of the Surgeon General 2004, U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Washington, DC, Available at: wwwcdcgov/tobacco/sgr/sgr_2004/indexhtm [CDC Publication No. 7829].
5. Samet J.M. Health benefits of smoking cessation. Clinics in Chest Medicine 1991, 12:669-679.
6. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 2009, 361:947-957.
7. Sun S., Schiller J.H., Gazdar A.F. Lung cancer in never smokers-a different disease. Nature Reviews Cancer 2007, 7:778-790.
8. Toh C.K., Gao F., Lim W.T., et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. Journal of Clinical Oncology 2006, 24:2245-2251.
9. Yano T., Miura N., Takenaka T., et al. Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer 2008, 113:1012-1018.
10. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010, 127:2893-2917.
11. Scagliotti G.V., Longo M., Novello S. Nonsmall cell lung cancer in never smokers. Current Opinion in Oncology 2009, 21:99-104.
12. Toh C.K., Wong E.H., Lim W.T., et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest 2004, 126:1750-1756.
13. Wakelee H.A., Chang E.T., Gomez S.L., et al. Lung cancer incidence in never smokers. Journal of Clinical Oncology 2007, 25:472-478.
14. Zell J.A., Ou S.H., Ziogas A., Anton-Culver H. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. Journal of Clinical Oncology 2005, 23:8396-8405.
15. Radzikowska E., Glaz P., Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20561 cases. Annals of Oncology 2002, 13:1087-1093.
16. Boffetta P., Jarvholm B., Brennan P., Nyren O. Incidence of lung cancer in a large cohort of non-smoking men from Sweden. International Journal of Cancer 2001, 94:591-593.
17. Peto R., Darby S., Deo H., Silcocks P., Whitley E., Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000, 321:323-329.
18. Antony G.K., Bertino E., Franklin M., Otterson G.A., Dudek A.Z. Small cell lung cancer in never smokers: report of two cases. Journal of Thoracic Oncology 2010, 5:747-748.
19. Subramanian J., Velcheti V., Gao F., Govindan R. Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology 2007, 2:827-830.
20. Santoro I.L., Ramos R.P., Franceschini J., Jamnik S., Fernandes A.L. Non-small cell lung cancer in never smokers: a clinical entity to be identified. Clinics (Sao Paulo) 2011, 66:1873-1877.
21. Bryant A., Cerfolio R.J. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007, 132:185-192.
22. Meguid R.A., Hooker C.M., Harris J., et al. Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers. Chest 2010, 138:500-509.
23. Sobue T., Yamamoto S., Hara M., Sasazuki S., Sasaki S., Tsugane S. Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. International Journal of Cancer 2002, 99:245-251.
24. Liu N.S., Spitz M.R., Kemp B.L., et al. Adenocarcinoma of the lung in young patients: the M. D. Anderson experience. Cancer 2000, 88:1837-1841.
25. Nordquist L.T., Simon G.R., Cantor A., Alberts W.M., Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004, 126:347-351.
26. Thun M.J., Henley S.J., Burns D., Jemal A., Shanks T.G., Calle E.E. Lung cancer death rates in lifelong nonsmokers. Journal of the National Cancer Institute 2006, 98:691-699.
27. Thun M.J., Hannan L.M., Adams-Campbell L.L., et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLOS Medicine 2008, 5:e185.
28. Etzel C.J., Lu M., Merriman K., Liu M., Vaporciyan A., Spitz M.R. An epidemiologic study of early onset lung cancer. Lung Cancer 2006, 52:129-134.
29. Thomas J.L., Guo H., Carmella S.G., et al. Metabolites of a tobacco-specific lung carcinogen in children exposed to secondhand or thirdhand tobacco smoke in their homes. Cancer Epidemiology, Biomarkers and Prevention 2011, 20:1213-1221.
30. Oberg M., Jaakkola M.S., Woodward A., Peruga A., Pruss-Ustun A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet 2011, 377:139-146.
31. Vineis P., Hoek G., Krzyzanowski M., et al. Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study. Environmental Health 2007, 6:7.
32. Hackshaw A.K., Law M.R., Wald N.J. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997, 315:980-988.
33. International Agency for Research on Cancer Tobacco smoke and involuntary smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2004, 83:1-1438.
34. Vineis P., Alavanja M., Buffler P., et al. Tobacco and cancer: recent epidemiological evidence. Journal of the National Cancer Institute 2004, 96:99-106.
35. Kawai H., Ishii A., Washiya K., et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clinical Cancer Research 2005, 11:5084-5089.
36. Wu C.T., Chang Y.L., Shih J.Y., Lee Y.C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. Journal of Thoracic and Cardiovascular Surgery 2005, 130:979-986.
37. Ali G., Donati V., Loggini B., et al. Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Human Pathology 2008, 39:1465-1473.
38. Stabile L.P., Davis A.L., Gubish C.T., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Research 2002, 62:2141-2150.
39. Omoto Y., Kobayashi Y., Nishida K., et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochemical and Biophysical Research Communications 2001, 285:340-347.
40. Samet J.M., Avila-Tang E., Boffetta P., et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clinical Cancer Research 2009, 15:5626-5645.
41. Tokuhata G.K., Lilienfeld A.M. Familial aggregation of lung cancer in humans. Journal of the National Cancer Institute 1963, 30:289-312.
42. Amos C.I., Xu W., Spitz M.R. Is there a genetic basis for lung cancer susceptibility. Recent Results in Cancer Research 1999, 151:3-12.
43. Matakidou A., Eisen T., Houlston R.S. Systematic review of the relationship between family history and lung cancer risk. British Journal of Cancer 2005, 93:825-833.
44. Hung R.J., McKay J.D., Gaborieau V., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452:633-637.
45. Amos C.I., Wu X., Broderick P., et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q251. Nature Genetics 2008, 40:616-622.
46. McKay J.D., Hung R.J., Gaborieau V., et al. Lung cancer susceptibility locus at 5p15.33. Nature Genetics 2008, 40:1404-1406.
47. Hsiung C.A., Lan Q., Hong Y.C., et al. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLOS Genetics 2010, 6.
48. Wang Y., Broderick P., Webb E., et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nature Genetics 2008, 40:1407-1409.
49. Sasaki T., Gan E.C., Wakeham A., Kornbluth S., Mak T.W., Okada H. HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes and Development 2007, 21:848-861.
50. Wang Y.C., Hsu H.S., Chen T.P., Chen J.T. Molecular diagnostic markers for lung cancer in sputum and plasma. Annals of the New York Academy of Sciences 2006, 1075:179-184.
51. Li Y., Sheu C.C., Ye Y., et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncology 2010, 11:321-330.
52. Blackhall F.H., Merry C.L., Davies E.J., Jayson G.C. Heparan sulfate proteoglycans and cancer. British Journal of Cancer 2001, 85:1094-1098.
53. Vineis P., Bartsch H., Caporaso N., et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994, 369:154-156.
54. Hung R.J., Boffetta P., Brockmoller J., et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis 2003, 24:875-882.
55. Chen B., Qiu L.X., Li Y., et al. The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects. Lung Cancer 2010, 70:247-252.
56. Zhou W., Liu G., Miller D.P., et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiology, Biomarkers and Prevention 2003, 12:359-365.
57. Qian B., Zhang H., Zhang L., Zhou X., Yu H., Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 2011, 73:138-146.
58. Gorlova O.Y., Weng S.F., Zhang Y., Amos C.I., Spitz M.R., Wei Q. DNA repair capacity and lung cancer risk in never smokers. Cancer Epidemiology, Biomarkers and Prevention 2008, 17:1322-1328.
59. Oh S.S., Chang S.C., Cai L., et al. Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. International Journal of Cancer 2010, 127:2169-2182.
60. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. New England Journal of Medicine 2008, 358:1160-1174.
61. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 2004, 350:2129-2139.
62. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
63. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer 2007, 7:169-181.
64. Pallis A.G., Fennell D.A., Szutowicz E., Leighl N.B., Greillier L., Dziadziuszko R. Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. British Journal of Cancer 2011, 105:1-8.
65. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Research 2004, 64:8919-8923.
66. Rosell R., Moran T., Queralt C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. New England Journal of Medicine 2009, 361:958-967.
67. Fukuoka M., Wu Y.L., Thongprasert S., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Journal of Clinical Oncology 2011, 29:2866-2874.
68. Pham D., Kris M.G., Riely G.J., et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. Journal of Clinical Oncology 2006, 24:1700-1704.
69. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology 2001, 2:127-137.
70. Lenferink A.E., Pinkas-Kramarski R., van de Poll M.L., et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO Journal 1998, 17:3385-3397.
71. Tzahar E., Waterman H., Chen X., et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Molecular and Cellular Biology 1996, 16:5276-5287.
72. Stephens P., Hunter C., Bignell G., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004, 431:525-526.
73. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncology 2011, 12:175-180.
74. Shimamura T., Ji H., Minami Y., et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Research 2006, 66:6487-6491.
75. Wang S.E., Narasanna A., Perez-Torres M., et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10:25-38.
76. Camidge D.R., Doebele R.C. Treating ALK-positive lung cancer-early successes and future challenges. Nature Reviews Clinical Oncology 2012, 9:268-277.
77. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
78. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. Journal of Clinical Oncology 2009, 27:4232-4235.
79. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of Medicine 2010, 363:1693-1703.
80. Birchmeier C., O'Neill K., Riggs M., Wigler M. Characterization of ROS1 cDNA from a human glioblastoma cell line. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:4799-4803.
81. Rikova K., Guo A., Zeng Q., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
82. Bergethon K., Shaw A.T., Ignatius Ou S.H., et al. ROS1 rearrangements define a unique molecular class of lung cancers. Journal of Clinical Oncology 2012, 30:863-870.
83. Tammemagi C.M., Neslund-Dudas C., Simoff M., Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004, 125:27-37.
84. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine 2005, 353:123-132.
85. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
86. Kawaguchi T., Takada M., Kubo A., et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. Journal of Thoracic Oncology 2010, 5:620-630.
87. Hanagiri T., Sugio K., Mizukami M., et al. Significance of smoking as a postoperative prognostic factor in patients with non-small cell lung cancer. Journal of Thoracic Oncology 2008, 3:1127-1132.
88. Janjigian Y.Y., McDonnell K., Kris M.G., et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer 2010, 116:670-675.
89. Scagliotti G.V., De Marinis F., Rinaldi M., et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. Journal of Thoracic Oncology 2009, 4:1568-1571.
90. Syrigos K.N., Vansteenkiste J., Parikh P., et al. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Annals of Oncology 2010, 21:556-561.
91. Kubota K., Kawahara M., Ogawara M., et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncology 2008, 9:1135-1142.
92. Yang C.H., Simms L., Park K., Lee J.S., Scagliotti G., Orlando M. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. Journal of Thoracic Oncology 2010, 5:688-695.
93. Tsao A.S., Liu D., Lee J.J., Spitz M., Hong W.K. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006, 106:2428-2436.
94. Pallis A.G., Syrigos K.N. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer 2013, 80:120-130.
95. Darby S., Hill D., Auvinen A., et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ 2005, 330:223.
96. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. Pathology and genetics tumours of the lung, pleura, thymus and heart. WHO Classification of Tumors 2004, IARC Press, Lyon. P. Kleihues, L.H. Sobin (Eds.).
97. Ko Y.C., Cheng L.S., Lee C.H., et al. Chinese food cooking and lung cancer in women nonsmokers. American Journal of Epidemiology 2000, 151:140-147.
98. Kleinerman R.A., Wang Z., Wang L., et al. Lung cancer and indoor exposure to coal and biomass in rural China. Journal of Occupational and Environmental Medicine 2002, 44:338-344.
99. Lissowska J., Bardin-Mikolajczak A., Fletcher T., et al. Lung cancer and indoor pollution from heating and cooking with solid fuels: the IARC international multicentre case-control study in Eastern/Central Europe and the United Kingdom. American Journal of Epidemiology 2005, 162:326-333.
100. Vineis P., Forastiere F., Hoek G., Lipsett M. Outdoor air pollution and lung cancer: recent epidemiologic evidence. International Journal of Cancer 2004, 111:647-652.
101. Cheng Y.W., Chiou H.L., Sheu G.T., et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Research 2001, 61:2799-2803.
102. Liang H.Y., Li X.L., Yu X.S., et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. International Journal of Cancer 2009, 125:2936-2944.
103. Lee M.Y., Lin K.D., Hsiao P.J., Shin S.J. The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism - Clinical and Experimental 2012, 61:242-249.
104. Gorlova O.Y., Weng S.F., Hernandez L., Spitz M.R., Forman M.R. Dietary patterns affect lung cancer risk in never smokers. Nutrition and Cancer 2011, 63:842-849.